Fung Man C, Sakata Tohru
Oncology Department, Lilly Research Laboratories-Japan, Eli Lilly Japan, Sanomiya Plaza Building, 7-1-5 Isogamidori, Chuo-ku, Kobe 651-0086, Japan.
J Hepatobiliary Pancreat Surg. 2002;9(1):61-75. doi: 10.1007/s005340200006.
Pancreatic cancer represents a major challenge to oncologists because of its high chemoresistant nature and dismal outcomes. Conventional therapy for advanced disease relied for a long time on palliative 5-fluorouracil (5-FU)-based chemotherapy, but with unsatisfactory results. The introduction of the novel antimetabolite gemcitabine provides new optimism for patients with advanced pancreatic cancer, as multiple clinical trials have demonstrated the superiority of gemcitabine over 5-FU and other agents for these patients. The benefits of gemcitabine over conventional therapies include improved response rate and enhanced survival, as well as improvement in disease-related symptoms and quality of life in these patients. With these data, gemcitabine is widely accepted worldwide as the therapy of choice by many oncologists for advanced pancreatic cancer. The current review presents an overview of the clinical studies of gemcitabine over the past decade for the treatment of patients with advanced pancreatic cancer. Other investigational regimens or uses (e.g., fixed dose-rate infusion, intraarterial infusion, adjuvant use, chemo-radiation, etc) are also reviewed.
胰腺癌因其高度的化学抗性和糟糕的预后结果，对肿瘤学家而言是一项重大挑战。长期以来，晚期疾病的传统治疗依赖于以姑息性5-氟尿嘧啶（5-FU）为基础的化疗，但结果并不理想。新型抗代谢药物吉西他滨的引入为晚期胰腺癌患者带来了新的希望，因为多项临床试验已证明吉西他滨对这些患者优于5-FU和其他药物。吉西他滨相对于传统疗法的益处包括提高缓解率、延长生存期，以及改善这些患者与疾病相关的症状和生活质量。基于这些数据，吉西他滨在全球范围内被许多肿瘤学家广泛接受为晚期胰腺癌的首选治疗方法。本综述概述了过去十年中吉西他滨治疗晚期胰腺癌患者的临床研究。其他研究方案或用途（如固定剂量率输注、动脉内输注、辅助使用、化疗放疗等）也在综述范围内。
